These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 12666409)

  • 1. [Advanced glycosylation end products and chronic complications of diabetes mellitus].
    Méndez JD
    Gac Med Mex; 2003; 139(1):49-55. PubMed ID: 12666409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced glycation end-products and the progress of diabetic vascular complications.
    Jakus V; Rietbrock N
    Physiol Res; 2004; 53(2):131-42. PubMed ID: 15046548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
    Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
    Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view.
    Chilelli NC; Burlina S; Lapolla A
    Nutr Metab Cardiovasc Dis; 2013 Oct; 23(10):913-9. PubMed ID: 23786818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of AGEs formation by natural products.
    Nagai R; Shirakawa J; Ohno R; Moroishi N; Nagai M
    Amino Acids; 2014 Feb; 46(2):261-6. PubMed ID: 23504149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced glycation end products and diabetic complications.
    Stitt AW; Jenkins AJ; Cooper ME
    Expert Opin Investig Drugs; 2002 Sep; 11(9):1205-23. PubMed ID: 12225243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advanced glycation end products and hyperglycaemia].
    Omsland TK; Bangstad HJ; Berg TJ; Kolset SO
    Tidsskr Nor Laegeforen; 2006 Jan; 126(2):155-8. PubMed ID: 16415936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Causes and treatment of diabetic complications].
    Sakamoto N
    Nihon Naika Gakkai Zasshi; 1989 Nov; 78(11):1540-3. PubMed ID: 2693554
    [No Abstract]   [Full Text] [Related]  

  • 9. [Protein glycation--clinical and chemical aspects].
    Szymańska U; Boratyński J
    Postepy Hig Med Dosw; 1999; 53(5):689-703. PubMed ID: 10645144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Mechanisms of Inhibition of Advanced Glycation End Products Formation through Polyphenols in Hyperglycemic Condition.
    Khangholi S; Majid FA; Berwary NJ; Ahmad F; Aziz RB
    Planta Med; 2016 Jan; 82(1-2):32-45. PubMed ID: 26550791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid glycation and protein glycation in diabetes and atherosclerosis.
    Miyazawa T; Nakagawa K; Shimasaki S; Nagai R
    Amino Acids; 2012 Apr; 42(4):1163-70. PubMed ID: 20957396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine.
    Booth AA; Khalifah RG; Hudson BG
    Biochem Biophys Res Commun; 1996 Mar; 220(1):113-9. PubMed ID: 8602828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
    Cameron NE; Gibson TM; Nangle MR; Cotter MA
    Ann N Y Acad Sci; 2005 Jun; 1043():784-92. PubMed ID: 16037306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microvascular complications of diabetes.
    He Z; King GL
    Endocrinol Metab Clin North Am; 2004 Mar; 33(1):215-38, xi-xii. PubMed ID: 15053904
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
    Yamagishi S
    Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design.
    Khalifah RG; Chen Y; Wassenberg JJ
    Ann N Y Acad Sci; 2005 Jun; 1043():793-806. PubMed ID: 16037307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tannins and vascular complications of Diabetes: An update.
    Laddha AP; Kulkarni YA
    Phytomedicine; 2019 Mar; 56():229-245. PubMed ID: 30668344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.
    Degenhardt TP; Alderson NL; Arrington DD; Beattie RJ; Basgen JM; Steffes MW; Thorpe SR; Baynes JW
    Kidney Int; 2002 Mar; 61(3):939-50. PubMed ID: 11849448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications.
    Friedman EA
    Diabetes Care; 1999 Mar; 22 Suppl 2():B65-71. PubMed ID: 10097902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced glycation end products in clinical nephrology.
    Kalousová M; Zima T; Tesar V; Stípek S; Sulková S
    Kidney Blood Press Res; 2004; 27(1):18-28. PubMed ID: 14679311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.